{"id":68952,"date":"2026-03-03T07:29:50","date_gmt":"2026-03-03T07:29:50","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&p=68952"},"modified":"2026-05-21T07:14:11","modified_gmt":"2026-05-21T07:14:11","slug":"semax","status":"publish","type":"product","link":"https:\/\/medsbase.com\/da\/semax\/","title":{"rendered":"Semax"},"content":{"rendered":"

<\/p>\n

\n

Quick Answer \u2014 What is Semax?<\/h3>\n

Semax<\/strong> is a synthetic heptapeptide based on the 4\u201310 fragment of adrenocorticotropic hormone (ACTH). Developed at the Institute of Molecular Genetics in Russia, it is a nootropic and neuroprotective research peptide best known for potent BDNF elevation<\/strong> og intranasal CNS delivery<\/strong>. Approved in Russia as a stroke-recovery drug \u2014 not FDA-approved. Supplied in 5\u00a0mg to 10\u00a0mg lyophilized vials for laboratory research use only.<\/p>\n<\/div>\n

Hvad du f\u00e5r med MedsBase:<\/strong> Forskningsgrad lyofiliserede peptider \u00b7 HPLC \u226599% renhed (COA p\u00e5 anmodning) \u00b7 Diskret temperaturstabil emballage \u00b7 Verdensomsp\u00e6ndende peptidkur\u00e9r \u00b7 1.400+ verificeret kundeanmeldelser<\/a><\/div>\n

\ud83d\udce6 Hver ordre er d\u00e6kket af vores Reshipment Assurance Policy<\/strong><\/a> \u2014 hvis din pakke ikke ankommer inden for 20 hverdage, sender vi en erstatning.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Specifikation<\/th>\nDetaljer<\/th>\n<\/tr>\n<\/thead>\n
CAS-nummer<\/strong><\/td>\n80714-61-0<\/td>\n<\/tr>\n
Molekyl\u00e6r formel<\/strong><\/td>\nC37<\/sub>H51<\/sub>N9<\/sub>O10<\/sub>S<\/td>\n<\/tr>\n
Molekylv\u00e6gt<\/strong><\/td>\n813.93 Da<\/td>\n<\/tr>\n
Sekvens<\/strong><\/td>\nMet-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP)<\/td>\n<\/tr>\n
Form<\/strong><\/td>\nLyofiliseret pulver (eller som leveret)<\/td>\n<\/tr>\n
Renhed<\/strong><\/td>\n\u226599% (HPLC verificeret, COA p\u00e5 anmodning)<\/td>\n<\/tr>\n
Opbevaring<\/strong><\/td>\nLyofiliseret: 2\u20138 \u00b0C (k\u00f8leskab) til arbejdslager; \u221220 \u00b0C til langtidsopbevaring af u\u00e5bnede flasker. Rekonstitueret: 2\u20138 \u00b0C, brug inden for ~30 dage. Beskyt mod lys. Frys ikke\u2013opt\u00f8 den rekonstituerede opl\u00f8sning.<\/td>\n<\/tr>\n
Opl\u00f8selighed<\/strong><\/td>\nBakteriostatisk vand (anbefales) eller sterilt vand til kortere brugsperioder<\/td>\n<\/tr>\n
Til forskningsbrug<\/strong><\/td>\nKun til laboratorieforskningsbrug. Ikke til humant eller veterin\u00e6rt diagnostisk eller terapeutisk brug.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

What Is Semax?<\/h2>\n

Semax<\/strong> (Met-Glu-His-Phe-Pro-Gly-Pro, sequence MEHFPGP) is a synthetic seven-amino-acid peptide developed in the 1980s at the Russian Institute of Molecular Genetics by Mekhedov, Malyshev, and collaborators. It is a structural analog of the ACTH 4\u201310 fragment \u2014 the central biologically-active region of adrenocorticotropic hormone \u2014 modified with a C-terminal Pro-Gly-Pro sequence that extends half-life and improves CNS penetration.<\/p>\n

Semax is approved in the Russian Federation<\/strong> as a prescription medication for acute ischemic stroke and cognitive-disorder indications, sold under the trade names Semax and Semaks. It is not approved by the FDA, EMA, or other Western regulators, so Western researchers access it through research-use-only supply. Molecular weight approximately 813.9\u00a0Da. Supplied as a high-purity lyophilized powder for reconstitution with bacteriostatic water. Semax is kun til laboratorieforskningsbrug<\/strong> outside its approved jurisdiction. For mechanism, clinical history, and research context, see our Semax research guide<\/a>.<\/p>\n

Mechanism of Action \u2014 BDNF, Melanocortin, and CNS Penetration<\/h2>\n

Semax’s pharmacology combines three features that make it unusually well-studied for a nootropic research peptide:<\/p>\n